source
- FDA approves first mRNA seasonal flu vaccine, mFlusiva, a year after funding cutsThe U.S. Food and Drug Administration granted approval to mFlusiva, the first mRNA‑based seasonal influenza vaccine, after its advisory committee voted unanimously that the benefits outweigh the ri…
- LifeMine secures $263M to advance fungal-derived organ transplant drugLifeMine Therapeutics announced it has closed two venture financings that together raised $263 million. The capital will be used to push its experimental therapy, LIFE-001, further along the develo…